Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
about
Data from subjects receiving intrathecal laronidase for cervical spinal stenosis due to mucopolysaccharidosis type I.Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.Phase I and II clinical trials for the mucopolysaccharidoses.Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.
P2860
Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@ast
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@en
type
label
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@ast
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@en
prefLabel
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@ast
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@en
P2093
P2860
P1476
Safety of laronidase delivered ...... is in mucopolysaccharidosis I.
@en
P2093
Agnes H Chen
Alla Victoroff
Anton Mlikotic
David E Naylor
Ilkka Kaitila
Jacqueline Madden
Merry B Passage
Mucopolysaccharidosis I Intrathecal Research Collaborative
Patricia I Dickson
Paul Harmatz
P2860
P356
10.1016/J.YMGME.2015.07.005
P577
2015-07-26T00:00:00Z